Daniel R. Wagner   卢森堡中心医院
    <International Circulation>: BNP has been one of the most attractive parameters and researches of heart failure management， so can we use BNP as a bio marker or a prognosis predictor of heart failure definitively based on the currently available data， in your opinion?

  《国际循环》： BNP已成为心力衰竭管理研究中最有吸引力的参数之一。那么，基于目前已有数据，您认为我们能否明确将BNP用作心力衰竭的生物标志物或预后预测因子？

    Dr. Wagner: The data is quite promising but there are still some questions about the age limit which remain unanswered.

    Dr. Wagner：数据是相当有希望的，但还有一些有关年龄限制的问题尚有待解答。

    <International Circulation>:Do you have any comment on the value of BNP guided treatment of heart failure in which modalities could lower or target BNP levels? 

  《国际循环》：您如何评价BNP指导的心力衰竭治疗的价值？哪些方法可降低或靶向BNP水平？

    Dr. Wagner: The big question today was the BNP and heart failure with preserved ejection fraction and it’s really not clear what to do， and that for me is the biggest question.

    Dr. Wagner：如今的大问题是BNP和射血分数保留的心力衰竭，的确尚不清楚要做什么，这对我来说是最大的问题。

[1]  [2]  下一页